Ozenoxacin

What is Ozenoxacin?[edit | edit source]

Ozenoxacin (XEPI) is a quinolone antimicrobial used for the topical treatment of impetigo.

This medicine is used for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.

Ozenoxacin is a quinolone antimicrobial drug.
The mechanism of action involves the inhibition of bacterial DNA replication enzymes, DNA gyrase A and topoisomerase IV.
Ozenoxacin has been shown to be bactericidal against S. aureus and S. pyogenes organisms.

Recommended Dosageː

Apply a thin layer of XEPI topically to the affected area twice daily for five days.
Affected area may be up to 100 cm2 in adult and pediatric patients 12 years of age and older or 2% of the total body surface area and not exceeding 100 cm2 in pediatric patients less than 12 years of age.

Administration

Use XEPI as directed by the healthcare practitioner.
As with any topical medication, patients and caregivers should wash their hands after application if the hands are not the area for treatment.
XEPI is for external use only.
Do not swallow XEPI or use it in the eyes, on the mouth or lips, inside the nose, or inside the female genital area.
Apply a thin layer of XEPI topically to the affected area.
Wash hands after applying XEPI cream.
XEPI cream is for topical use only.
Not for oral, ophthalmic, intranasal, or intravaginal use.
The treated area may be covered with a sterile bandage or gauze dressing.

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

The prolonged use of XEPI may result in overgrowth of nonsusceptible bacteria and fungi.
If such infections occur during therapy, discontinue use and institute appropriate supportive measures.

Any sign or symptom of overdose, either topically or by accidental ingestion, should be treated symptomatically.
No specific antidote is known.

There are no available data on the use of XEPI in pregnant women to inform a drug associated risk.

The safety and effectiveness of XEPI in the treatment of impetigo have been established in pediatric patients 2 months to 17 years of age.
The safety and effectiveness of XEPI in pediatric patients younger than 2 months of age have not been established.

OZENOXACIN

Who manufactures and distributes this medicine?

Manufactured for :

Store at 20ºC - 25ºC (68ºF - 77ºF); excursions permitted to 15ºC to 30ºC (59ºF - 86ºF).

Ozenoxacin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.